Table 1 Baseline characteristics of the included studies
Trial name | Treatment duration, (weeks) | Backgroud therapy | Study arms | Patients (n) | Age (year) | Body weight (kg) | Diabetes duration (years) | Baseline HbA1c ( %) |
|---|---|---|---|---|---|---|---|---|
Sorli 2017 NCT02054897 | 30 | diet and exercise | Semaglutide 0.5Â mg | 128 | 54.6 | 89.8 | 4.81 | 8.1 |
Semaglutide 1.0Â mg | 130 | 52.7 | 96.9 | 3.62 | 8.1 | |||
placebo | 129 | 53.9 | 89.1 | 4.06 | 8.0 | |||
Ahren 2017 NCT01930188 | 56 | MET ± TZD | Semaglutide 0.5 mg | 409 | 54.8 | 89.9 | 6.4 | 8.0 |
Semaglutide 1.0Â mg | 409 | 56.0 | 89.2 | 6.7 | 8.0 | |||
Sitagliptin 100Â mg | 407 | 54.6 | 89.3 | 6.6 | 8.2 | |||
Ahmann 2018 NCT01885208 | 56 | MET ± (TZD or SU) | Semaglutide 0.5 mg | 404 | 56.4 | 96.2 | 9.0 | 8.4 |
Exenatide 2Â mg | 405 | 56.7 | 95.4 | 9.4 | 8.3 | |||
Aroda 2017 NCT02128932 | 30 | MET ± SU | Semaglutide 0.5 mg | 362 | 56.5 | 93.7 | 7.8 | 8.1 |
Semaglutide 1.0Â mg | 360 | 56.7 | 94.0 | 9.3 | 8.3 | |||
Insulin | 360 | 56.2 | 92.6 | 8.6 | 8.1 | |||
Rodbard 2018 NCT02305381 | 30 | BI ± MET | Semaglutide 0.5 mg | 132 | 59.1 | 92.7 | 12.9 | 8.4 |
Semaglutide 1.0Â mg | 131 | 58.5 | 92.5 | 13.7 | 8.3 | |||
placebo | 133 | 58.8 | 89.9 | 13.3 | 8.4 | |||
Marso 2016 NCT01720446 | 104 | <2 OADs ± (BI or PRI) | Semaglutide 0.5 mg | 826 | 64.6 | 91.8 | 14.3 | 8.7 |
Semaglutide 1.0Â mg | 822 | 64.7 | 92.8 | 14.1 | 8.7 | |||
Placebo 0.5Â mg | 824 | 64.8 | 91.8 | 14.0 | 8.7 | |||
Placebo 1.0Â mg | 825 | 64.4 | 91.9 | 13.2 | 8.7 | |||
Partley 2018 NCT02648204 | 40 | MET | Semaglutide 0.5Â mg | 301 | 56 | 96.4 | 7.7 | 8.3 |
Semaglutide 1.0Â mg | 299 | 55 | 95.5 | 7.0 | 8.2 | |||
Dulaglutide 0.5Â mg | 300 | 55 | 95.6 | 7.3 | 8.2 | |||
Dulaglutide 1.0Â mg | 299 | 56 | 93.4 | 7.6 | 8.2 | |||
Lingvay 2019 NCT03136484 | 52 | MET | Semaglutide 1.0Â mg | 394 | 55.7 | 90.6 | 7.5 | 8.3 |
Canagliflozin 100Â mg | 394 | 57.5 | 89.8 | 7.2 | 8.2 | |||
Zinman 2019 NCT03086330 | 30 | SGLT-2 inhibitor | Semaglutide 1.0Â mg | 151 | 57.5 | 89.6 | 9.8 | 8.0 |
placebo | 151 | 56.6 | 93.8 | 9.6 | 8.1 | |||
Capehorn 2020 | 30 | MET ± SU ± SGLT-2 | Semaglutide 1.0 mg | 290 | 60.1 | 96.9 | 9.6 | 8.2 |
Liraglutide 1.2Â mg | 287 | 58.9 | 97.2 | 8.9 | 8.3 | |||
Nauck 2016 NCT00696657 | 12 | diet and exercise ± MET | placebo | 46 | 55.3 | 90.5 | 2.4 | 8.1 |
Semaglutide 0.4Â mg | 48 | 53.8 | 87.0 | 2.0 | 8.1 | |||
Semaglutide 0.8Â mg | 43 | 55.9 | 85.7 | 2.6 | 8.0 | |||
Liraglutide 1.2Â mg | 45 | 54.8 | 90.5 | 3.3 | 8.0 | |||
Liraglutide 1.8Â mg | 50 | 54.3 | 87.2 | 2.5 | 8.1 | |||
Ji 2020 NCT03061214 | 30 | MET | Semaglutide 0.5Â mg | 288 | 53.0 | 77.6 | 6.3 | 8.1 |
Semaglutide 1.0Â mg | 290 | 53.0 | 76.1 | 6.7 | 8.1 | |||
Sitagliptin 100Â mg | 290 | 53.1 | 75.5 | 6.1 | 8.1 | |||
Lingvay 2018 NCT02461589 | 26 | diet and exercise ± MET | placebo | 129 | 57.1 | 94.0 | 7.1 | 8.1 |
Semaglutide 0.05Â mg/d | 64 | 57.5 | 93.4 | 6.5 | 7.9 | |||
Semaglutide 0.1Â mg/d | 63 | 58.4 | 92.4 | 8.1 | 7.9 | |||
Liraglutide 1.2Â mg | 64 | 53.7 | 96.7 | 6.9 | 8.1 | |||
Liraglutide 1.8Â mg | 65 | 55.8 | 93.4 | 6.6 | 8.1 | |||
Davies 2017 NCT01923181 | 26 | diet and exercise ± MET | Semaglutide 1.0 mg | 71 | 56.8 | 88.8 | 5.6 | 7.8 |
placebo | 69 | 58.9 | 93.8 | 6.7 | 8.0 | |||
Seino 2017 NCT02254291 | 30 | diet and exercise or OAD monotherapy | Semaglutide 0.5Â mg | 103 | 58.8 | 67.8 | 8.0 | 8.2 |
Semaglutide 1.0Â mg | 102 | 58.1 | 70.8 | 7.8 | 8.0 | |||
Sitagliptin 100Â mg | 103 | 57.9 | 69.4 | 8.1 | 8.2 | |||
Kaku 2018 NCT0220737 | 56 | SU or GLI or AGI or TZD | Semaglutide 0.5Â mg | 239 | 58.0 | 71.0 | 8.1 | 8.0 |
Semaglutide 1.0Â mg | 241 | 58.7 | 71.7 | 9.4 | 8.1 | |||
Additional OAD | 121 | 59.2 | 72.2 | 9.3 | 8.1 | |||
FrÃas 2021 NCT03987919 | 40 | MET | 5Â mg Tirzepatide | 461 | 56.3 | 925 | 9.1 | 8.32 |
10Â mg Tirzepatide | 459 | 57.2 | 94.8 | 8.4 | 8.3 | |||
15Â mg Tirzepatide | 464 | 55.9 | 93.8 | 8.7 | 8.26 | |||
1Â mg Semaglutide | 461 | 56.9 | 93.7 | 8.3 | 8.25 |